Eisenberger, Ute http://orcid.org/0000-0003-3862-6933
,
Budde, Klemens
Lehner, Frank
Sommerer, Claudia
Reinke, Petra
Witzke, Oliver
Wüthrich, Rudolf P.
Stahl, Rolf
Heller, Katharina
Suwelack, Barbara
Mühlfeld, Anja
Hauser, Ingeborg A.
Nadalin, Silvio
Porstner, Martina
Arns, Wolfgang
Funding for this research was provided by:
The ZEUS study was funded by Novartis Pharma GmbH, Nuernberg, Germany
Article History
Received: 12 September 2017
Accepted: 17 June 2018
First Online: 28 June 2018
Ethics approval and consent to participate
: All patients provided written informed consent. The study protocol was approved by the independent ethics committee or institutional review board for each center, and the procedures followed in the trial were in accordance with the Declaration of Helsinki 1975, as revised in 2008.
: The authors give full consent for publication.
: U Eisenberger has received travel expenses and honoraria from Novartis, TEVA, Astellas and Pfizer;K Budde has received research funds and/or honoraria from Abbvie, Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Fresenius, Genentech, Hexal, Novartis, Otsuka, Pfizer, Roche, Shire, Siemens, and Veloxis Pharma;F Lehner has received fees and honoraria from Novartis, Astellas, Roche and Sanofi;C Sommerer has received honoraria from Novartis, Chiesi and Sanofi.P Reinke has no conflicts of interest;O Witzke has received research funds and/or honoraria from Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Janssen-Cilag, MSD, Novartis, Pfizer, Roche and Shire;RP Wüthrich has received fees and honoraria from Astellas, Novartis and Roche;R Stahl has no conflicts of interest;K Heller has no conflicts of interest;B Suwelack has no conflicts of interest;A Mühlfeld has no conflicts of interest;IA Hauser has received honoraria or travel grants from Alexion, Astellas, Chiesi, Fresenius, Hexal, Roche, Novartis, Sanofi, Teva, and has received grant/research support from Novartis.S Nadalin has no conflicts of interest to declare;M Porstner is an employee of Novartis;W Arns has received study fees and honoraria from Novartis and Astellas.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.